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The current Bacillus anthracis vaccine consists largely of protective antigen (PA), the protein of anthrax
toxin that mediates entry of edema factor (EF) or lethal factor (LF) into cells. PA induces protective
antibody (Ab)-mediated immunity against Bacillus anthracis but has limited efficacy and duration. We
previously demonstrated that activation of CD1d-restricted natural killer-like T cells (NKT) with a
CD1d-binding glycolipid led to enhanced Ab titers specific for foreign antigen (Ag). We therefore tested
the hypothesis that activation of NKT cells with the CD1d ligand (-galactosylceramide [-GC]) at the
time of immunization improves PA-specific Ab responses. We observed that -GC enhanced PA-specific Ab
titers in C57BL/6 mice. In CD1d/ mice deficient in type I and type II NKT cells the anti-PA Ab response
was diminished. In J281/ mice expressing CD1d but lacking type I -GC-reactive NKT cells, -GC did
not enhance the Ab response. In vitro neutralization assays were performed and showed that the Ab titers
correlated with protection of macrophages against anthrax lethal toxin (LT). The neutralization capacity
of the Ab was further tested in lethal challenge studies, which revealed that NKT activation leads to
enhanced in vivo protection against LT. Anti-PA Ab titers, neutralization, and protection were then
measured over a period of several months, and this revealed that NKT activation leads to a sustained
protective Ab response. These results suggest that NKT-activating CD1d ligands could be exploited for the
development of improved vaccines for Bacillus anthracis that increase not only neutralizing Ab titers but
also the duration of the protection afforded by Ab.
The current AVA anthrax vaccine administered to U.S. mili-
tary personnel consists of the Bacillus anthracis protective antigen
(PA) and induces PA-specific antibody (Ab) titers sufficient to
neutralize anthrax toxin (28, 29). However, the anti-PA Ab titers
are not sustained, and individuals require administration of mul-
tiple booster vaccines to maintain toxin-neutralizing Ab titers
(http://www.anthrax.osd.mil/vaccine/schedule.asp#). Thus, there
is a need for improving the efficacy of the current anthrax vaccine.
PA is an 83-kDa protein that forms heptameric pores on the
surface of target cells expressing anthrax toxin receptors (cap-
illary morphogenesis protein 2 [CMG-2] and tumor endothe-
lial marker 8 [TEM-8]) (5, 6). PA heptamers interact with
lethal factor (LF) and edema factor (EF) to form lethal toxin
(LT) and edema toxin (ET), which together are referred to as
anthrax toxin (6). The PA heptamer facilitates entry of EF and
LF into the target cell. Following cell entry, EF generates
supraphysiological levels of cyclic AMP via the protein’s calm-
odulin-dependent adenylate cyclase activity (20). Within the
intoxicated cell LF functions as a zinc-dependent metallopro-
tease and cleaves mitogen-activated protein kinase kinases and
has recently been found to disrupt the inflammasome (10).
Both toxins are lethal in animal models and cause a broad
range of defects in target cells, including altered cell cycle, cell
growth, and survival and attenuated inflammatory responses
(24). Collectively these activities of anthrax toxin cripple the
host immune system and allow B. anthracis to grow to high
numbers in the bloodstream (6). Hence, immune neutraliza-
tion of PA prevents all of the detrimental effects of anthrax
edema toxin and lethal toxin, providing a crucial advantage to
the host during early stages of disease.
PA-specific Abs effectively neutralize LT and ET in vitro and
protect immunized animals in vivo following a lethal challenge
with the toxins (1, 4, 25, 26, 30, 33). There is a good correlation
between PA-specific Ab titers and toxin neutralization by sera
from patients who have survived B. anthracis infection (29).
Consequently, there is considerable interest in development of
efficacious vaccines which incorporate PA as the immunogen
but involve fewer immunizations, boost immunological mem-
ory, and prolong neutralizing Ab production while stimulating
a minimal inflammatory response (28, 29).
Recent work by our laboratory and others has shown that
activation of a specialized subset of T cells known as natural
killer-like T cells (NKT cells) improves Ab responses against
model and pathogen-derived antigens (3, 8, 13, 16, 17). More
recently, we and others have also demonstrated that B-cell
memory responses and the duration of plasma cell responses
are enhanced as a result of administration of an NKT-activat-
ing glycolipid known as -galactosylceramide (-GC) (8, 11).
The -GC ligand consists of a galactose headgroup with an
-anomeric linkage to hydrophobic sphingosine and acyl
chains. The lipid moiety is loaded into hydrophobic pockets in
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the CD1d molecule expressed by professional antigen-present-
ing cells, orienting the galactose headgroup for recognition by
NKT cells (14, 32). The predominant NKT subset is repre-
sented by the type I NKT cells, which express an invariant
V14, J18 T-cell antigen receptor (TCR) in mice and a V24,
J28 TCR in humans (14, 32). Type II NKT cells have variable
V usage, and while CD1d restricted they are thought to be
stimulated by a variety of glycolipids but are not stimulated by
-GC (14, 32).
In this study we therefore tested the hypothesis that coad-
ministration of -GC and PA leads to enhanced anti-PA Ab
titers and that the Ab produced neutralizes LT in vitro and
protects in vivo against a lethal challenge. Our results show
that NKT cells are required for generation of PA-specific LT-
neutralizing Abs and that activation of NKT cells with exoge-
nous CD1d ligand at the time of immunization boosts the
toxin-neutralizing Ab titer and leads to enhanced and sus-
tained in vivo protection against a lethal challenge with anthrax
toxin.
MATERIALS AND METHODS
Reagents. BL21 competent cells were purchased from Invitrogen (Carlsbad,
CA). pET15b plasmids encoding PA and LF were a gift from J. Collier (Harvard
Medical School) and have been described previously (5). The protein assay kit
was purchased from Bio-Rad Laboratories (Hercules, CA). The Pyrogent Ultra
Limulus amebocyte lysate kit was purchased from Lonza (Walkersville, MD).
-GC was purchased from Axorra Inc. (San Diego, CA). The purity, structural
integrity, and functionality of -GC have been described by us previously (18).
Horseradish peroxidase (HRP)-conjugated anti-IgG1 was purchased from
Southern Biotechnology (Birmingham, AL). Fluorochrome-conjugated mono-
clonal antibodies (MAbs) were purchased from BD Biosciences (San Jose, CA).
The FcR-blocking MAb (2.4G2) was purchased from BioXpres (West Lebanon,
NH). CD1d/-GC tetramers were provided by the NIAID Tetramer Facility
(Emory University, Atlanta, GA).
Expression and purification of PA and LF. Competent Escherichia coli (BL21)
cells transformed with the pET15b-rPA plasmid were grown at 37°C in Luria-
Bertani broth containing ampicillin (50 g/ml final concentration) with shaking
at 250 rpm in 2-liter baffled flasks. When the absorbance of the culture reached
1.0 at a wavelength of 600 nm, isopropyl -D-1-thiogalactopyranoside was added
to a final concentration of 0.1 mM to induce PA expression. Following induction
for 18 h at 16°C, BL21 bacteria were harvested by centrifugation at 15,000  g
at 4°C for 20 min. The supernatant was discarded and the pellet was then
resuspended gently in binding buffer (20 mM sodium phosphate, 0.5 M NaCl,
and 20 mM imidazole; pH 7.4). The resuspended cells were lysed using an
Emulsiflex C-3 homogenizer (Avestin, Ottawa, ON, Canada) at 4°C for four
complete cycles at 5,000 lb/in2 of pressure. The lysate was centrifuged at 15,000
g at 4°C for 40 min, and the supernatant was collected and further clarified using
a 0.45-m filter unit.
Filtered lysate was then loaded onto a 5-ml HisTrap FF column (GE Life-
Sciences, Piscataway, NJ) using a peristaltic pump set at a 5-ml/min flow rate.
The column was then washed with 30 ml of wash buffer (20 mM sodium phos-
phate, 0.5 M NaCl, and 40 mM imidazole; pH 7.4), and the protein was eluted
from the column in 5-ml fractions using elution buffer (20 mM sodium phos-
phate, 0.5 M NaCl, and 0.5 M imidazole; pH 7.4). The eluted fractions were
analyzed via SDS-PAGE, and those containing protein of the appropriate size
were collected and pooled. To avoid rapid precipitation of PA during desalting,
the isolated protein was placed in dialysis tubing with a 14-kDa cutoff and then
dialyzed at 4°C against 10 mM sodium phosphate, 2.7 mM KCl, 1.8 mM
KH2PO4, 0.25 M NaCl by stepping down the salt as follows: 2 h at 0.4 M NaCl,
2 h at 0.3 M NaCl, 2 h at 0.25 M NaCl, and 0.25 M NaCl overnight. To
concentrate purified PA, the dialyzed protein in the dialysis tubing was packed
into polyethylene glycol with a 35-kDa cutoff (VWR) for 1 to 2 h. The concen-
trated PA was centrifuged and filtered to remove debris, and the protein con-
centration was determined using the Bio-Rad assay. Endotoxin contamination
was reduced from purified PA by using an EndoTrap Red column (Lonza,
Walkersville, MD) following the manufacturer’s instructions. PA was eluted
from the column into phosphate-buffered saline (PBS) and subsequently passed
through a 0.22-m sterile filter, and the protein concentration of the sample was
determined. The concentration of residual endotoxin was determined using the
Limulus assay, which has a sensitivity of 0.06 endotoxin units/ml. PA was then
stored in aliquots at 20°C. The amount of lipopolysaccharide (LPS) remaining
in the PA samples after the Endotrap column removal procedure was such that
no more than 6 ng of LPS was administered to any mouse, an amount insufficient
to have adjuvant properties for Ab responses in mice (27). Western blot analysis
was used to confirm that sera from PA-immunized mice contained PA-specific
Ab (data not shown). Immunizations were also performed to compare PA before
LPS removal, PA after LPS removal, and PA after LPS removal and mixing with
freshly added LPS. These experiments showed that there was no significant LPS
contamination of our PA preparations that could exert adjuvant effects on
anti-PA Ab responses (data not shown).
LF was expressed and purified in an identical manner to PA except that the
pET15b-rLF plasmid was used for expression and the elution buffer for the
affinity column contained 0.2 M NaCl. Endotoxin association with LF was con-
siderably less than that observed for PA, and the concentration in the LF samples
following the endotoxin affinity column procedure was below the limit of detec-
tion.
Mice. C57BL/6 mice were purchased from the National Cancer Institute (Be-
thesda, MD). CD1d/ mice on the C57BL/6 genetic background have been
described previously (9) and were kindly provided by M. Exley (Harvard Medical
School). CD1d/ mice do not express CD1d on antigen-presenting cells and
therefore fail to develop either type I or type II NKT cells in the thymus and
export them to the periphery. J18/ mice were obtained from M. Kronenberg
(La Jolla Institute for Allergy and Immunology, La Jolla, CA) with kind permis-
sion from M. Taniguchi (RIKEN Institute, Japan) and are described in reference
7. J18/ mice express CD1d but fail to develop type I NKT cells because of a
targeted deletion in the J281 gene segment of the TCR. CD1d/ and J18/
mice were bred in the Animal Resource Center at the University of Oklahoma
Health Sciences Center (OUHSC). All procedures were approved by the Insti-
tutional Animal Care and Use Committee at OUHSC.
Immunizations and experimental schedule. Female mice of 6 to 10 weeks of
age were used, and five mice per group were immunized unless indicated oth-
erwise. A single subcutaneous (s.c.) immunization was administered over both
flanks on day zero immediately following collection of prebleed sera. Unless
indicated otherwise, immunizations consisted of 10 g of PA in 200 l of sterile
endotoxin-free PBS or PA mixed with 2 g of -GC. Mice were then bled at day
14 postimmunization and sera were obtained. On day 28 mice were bled and then
boosted s.c. with 5 g of PA in PBS and bled on days 33, 38, and 43 unless
indicated otherwise. At the end of the experimental period, mice were either
challenged with toxin or euthanized in order to obtain bone marrow and spleen
cells.
Retro-orbital eye bleed and serum collection. Mice were anesthetized using a
vaporized 4% isofluorane–96% oxygen mixture, and 100 l of blood was col-
lected by retro-orbital bleed with heparinized microcapillary tubes (Fisher Sci-
entific, Hampton, NH). Samples were transferred immediately to polypropylene
microcentrifuge tubes. Blood samples were incubated for 30 min at room tem-
perature and then allowed to clot overnight at 4°C before centrifugation at
13,000  g for 15 min at 4°C. Sera were withdrawn with a pipette and stored in
aliquots at 20°C.
Isolation of splenocytes. Spleens were harvested into Hanks balanced salt
solution buffer, and a single-cell suspension was obtained by mechanical disrup-
tion. Erythrocytes were removed by incubation with ammonium chloride lysis
buffer (0.16 M NH4Cl, 0.17 M Tris-HCl; pH 7.4) for 2 min at 37°C. After washing
in culture medium, cell viability was confirmed as 98% by trypan blue exclu-
sion. Cells were enumerated using a Beckman Coulter Z2 cell/particle counter
(Fullerton, CA).
ELISA. Immulon 4 enzyme-linked immunosorbent assay (ELISA) plates
(Dynex Technologies Inc., Chantilly, VA) were coated with PA at 10 g/ml in
binding buffer (0.1 M Na2HPO4; pH 9.0) overnight at 4°C before washing plates
and blocking for 2 h at room temperature with 1.0% (wt/vol) bovine serum
albumin (BSA) in PBS–0.05% (vol/vol) Tween 20. Sera were diluted 100- or
10,000-fold in PBS–0.05% (vol/vol) Tween and subjected to 2-fold serial dilutions
before adding the mixtures to PA-coated, preblocked plates. Plates were incu-
bated overnight at 4°C with diluted sera before washing four times in PBS–0.05%
(vol/vol) Tween 20. Plates were incubated for 1 h at room temperature with
HRP-conjugated anti-mouse IgG1 at a final concentration of 0.2 g/ml. Plates
were washed and developed for 5 min at room temperature using 90 l of
2,2-azinobis(3-ethylbenzthiazolinesulfonic acid) substrate per well (KPL, Gaith-
ersburg, MD). Reactions were stopped by addition of 110 l of a 10% (wt/vol)
SDS solution. Plates were analyzed using a Dynex MRX Revelation plate reader.
Endpoint titers were determined as an optical density (OD) of 	0.01 at 405 nm
(equivalent to the OD of a 1/200 dilution of prebleed sera). Individual Ab titers
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were plotted as geometric means using GraphPad Prism software. Differences in
Ab titers between two experimental groups were assessed for statistical signifi-
cance using a nonparametric Mann-Whitney U test. This test was used rather
than an analysis of variance because an independent control was performed for
each experimental group, as opposed to testing multiple groups against the same
control.
Flow cytometry. Cells were incubated at 4°C or room temperature at a density
of 107 cells/ml in RPMI plus 10% fetal calf serum (FCS) with the 2.4G2 MAb at
a final concentration of 20 g/ml. Fluorochrome-conjugated MAbs were added
at a 1:100 to a 1:500 dilution as appropriate or with allophycocyanin-conjugated
CD1d tetramer at a 1:250 dilution. After 1 h, unbound MAb was removed by
washing and centrifugation. Cells were fixed with 1% (wt/vol) paraformaldehyde
and analyzed using a Becton-Dickinson FACSCalibur (Palo Alto, CA).
In vitro toxin neutralization assay. Murine 264.7 macrophages were adjusted
to 106 cells/ml in Dulbecco’s modified Eagle’s medium (DMEM) containing 4
M L-glutamine, 10% FCS, and 40 g/ml gentamicin. One hundred thousand
cells in a 100-l volume were then seeded into 96-well culture plates and incu-
bated overnight with 5% CO2. Serial 2-fold dilutions of sera in media were made
(1/125 to 1/500) and mixed with lethal toxin at a final concentration of 1 to 16
g/ml of each subunit. The toxin mixture was then incubated for 1 h at room
temperature. Media were then removed from cell cultures and replaced with the
serum-toxin-medium mixture. Plates were incubated for a further 2 h at 37°C
before addition of cell counting Kit-8 reagents (Dojindo Technologies, Rockville,
MD). After 2 h of incubation, plates were read at an absorbance of 450 nm.
Differences in Ab titers between two experimental groups were assessed for
statistical significance using a nonparametric Mann-Whitney U test. As with the
ELISA experiments the Mann-Whitney U test was used because an independent
control was performed for each experimental group.
In vivo toxin challenge. The LF and PA subunits were mixed at a 1:1 molar
ratio in PBS. Unless indicated otherwise an amount of lethal toxin equivalent to
200 g of PA and in a 100-l volume was then administered by the intravenous
(i.v.) paraorbital route to mice. The mice were then monitored daily for the
duration of the experiment, and time to death or euthanasia was recorded.
RESULTS
NKT cells regulate anti-PA Ab responses. C57BL/6,
CD1d/, and J18/ mice were immunized with PA or PA
plus -GC and later boosted with PA alone before determining
anti-PA endpoint titers in serum (Fig. 1). We observed that PA
alone stimulated a strong Ab response in C57BL/6 mice and
that this was further enhanced 3- to 4-fold by the inclusion of
-GC during the primary immunization (Fig. 1a). Surprisingly,
there was a much weaker Ab response in CD1d/ mice than
in C57BL/6 mice immunized with PA alone (Fig. 1a to c).
Consistent with the lack of CD1d and NKT cells, -GC had no
effect on the Ab titer. These results were not due to subtly
different kinetics of the responses between groups, as the same
differences were observed in successive bleeds on days 38 and
43 postimmunization (Fig. 1b). The anti-PA endpoint titers in
PA-immunized C57BL/6 and J18/ mice were similar, sug-
gesting that type II cells are responsible for the defect in
CD1d/ mice and confirming that type I cells are responsible
for the -GC-stimulated enhancement (Fig. 1d).
The predominant anti-PA Ab subclass produced was IgG1,
and we therefore considered the possibility that the lack of
anti-PA IgG1 in CD1d/ mice could be reflected by an in-
crease in other Ig classes or subclasses. Significant IgG2b and
IgG2c responses did not occur in C57BL/6, CD1d/, or
J18/ mice immunized with PA alone or PA plus -GC
(data not shown). Our results showed that CD1d and type I
and/or type II NKT cells contribute to the vaccination-induced
anti-PA Ab response. In further controls, we determined if PA
directly modulated the activity of NKT cells in our system.
Although PA is not generally thought to impact cell physiol-
ogy, studies have shown that under specific circumstances PA
can be cytotoxic (31). At the dosage and routes of immuniza-
tion described, we did not observe any deleterious effects on
NKT cells, B cells, T cells, granulocytes, or dendritic cells (data
not shown).
FIG. 1. CD1d expression and NKT cells are required for optimal
production of PA-specific Abs. C57BL/6, CD1d/, and J18/ mice
were immunized s.c. with 10 g of PA or 10 g of PA plus 2 g of -GC
in a 100-l volume of sterile endotoxin-free PBS. Sera were collected
before immunization and on day 28 (data not shown). On day 28 mice
were then boosted with half the original dose of PA and sera collected
again on day 38 (d38) (a) and day 43 (b). ELISAs were performed to
determine the endpoint anti-PA IgG1 titer. Data points represent the
endpoint titers for individual mice. (c) Since only two CD1d/ mice were
used in the first experiment, additional groups of C57BL/6 and CD1d/
mice were immunized with PA and analyzed at day 43. (d) Responses in
J18/ mice are shown in a third experiment (also day 43 bleeds).
Geometric means are shown. Statistically significant differences between
experimental groups are indicated by asterisks.
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NKT cells contribute to and enhance Ab-mediated LT neu-
tralization. Sera from the immunized mice were then tested
for the ability to neutralize LT in vitro (Fig. 2). We observed
across several serum concentrations that type I NKT activation
with -GC led to an enhanced neutralization capacity (Fig. 2a).
Sera from CD1d/ mice immunized with PA plus -GC had
a poor neutralization capacity (Fig. 2a). We also observed in a
further experiment that sera from -GC-treated mice were
able to neutralize higher doses of toxin (Fig. 2b). When a final
toxin concentration of 16 g/ml was used in the assay (4- to
8-fold higher than in a typical assay), a greater separation of
the PA versus PA plus -GC groups was observed. There was
no apparent neutralization of the higher dose of the toxin by
sera from PA-immunized mice, whereas four of five sera from
mice immunized with PA plus -GC showed substantial toxin
neutralization.
Although it is well established that neutralizing Ab is re-
sponsible for protection against LT, we performed additional
controls to determine if NKT activation was causing any pro-
tective effects not attributable to Ab. We immunized B-cell-
deficient mice (MT strain), collected sera, and performed
ELISAs, neutralization assays, and in vivo challenges. As ex-
pected, there was no measurable Ig or anti-PA IgG or in vitro
neutralization activity (data not shown). There was also no in
vivo protection against LT, which demonstrated similar lethal-
ity as that for naïve C57BL/6 mice (data not shown).
NKT activation enhances in vivo protection against lethal
toxin. We initially determined the lethal dose of LT for our
studies, because the C57BL/6 mouse strain is more resistant
than some other strains (1). We observed that a 200-g dose
(of each subunit) was sufficient to kill 100% of naïve C57BL/6
mice within 3 to 5 days (Fig. 3a). We therefore challenged
C57BL/6 mice and CD1d/ mice that had previously been
immunized and boosted with PA alone (Fig. 3b). Surprisingly,
although the anti-PA Ab titers and neutralization capacities of
FIG. 2. CD1d-dependent NKT activation enhances in vitro lethal
toxin neutralization. Sera from experiments with results shown in Fig.
1 were used for in vitro neutralization assays as described in Materials
and Methods. Briefly, RAW267.4 macrophages were untreated (none)
or incubated with toxin alone or toxin mixed with sera from naïve and
immunized mice before assessing viability. Each data point represents
the percent cell viability conferred by serum from individual mice. All
samples were analyzed in duplicate. Asterisks indicate statistically sig-
nificant differences between PA-immunized versus PA plus -GC-
immunized groups. (a) Effect of serum dilution on resistance to the
toxin. (b) Effect of increasing toxin concentration on neutralization.
FIG. 3. CD1d-dependent activation of NKT cells enhances in vivo
protection against lethal toxin. Naïve and immunized mice were chal-
lenged i.v. with PA plus LF at the times indicated by arrows. Survival
was then monitored daily for the times indicated. (a) Naïve mice,
treated with 0, 50, 200, or 300 g of each toxin subunit. (b) Survival in
C57BL/6 and CD1d/ mice, previously immunized with PA and chal-
lenged with 200 g of each toxin subunit. (c) Survival in C57BL/6
previously immunized with PA alone or PA plus -GC and challenged
with the 200-g dose on day 0 and then the 100-g dose on day 1.
Numbers of mice per group are indicated.
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the sera were lower in CD1d/ and C57BL/6 mice, using
death as an end point did not distinguish between the two
experimental groups, since all immunized mice survived. How-
ever, with daily observations it was clear that C57BL/6 mice
appeared much healthier than CD1d/ mice. The C57BL/6
mice had ruffled fur, a hunched posture, and slower movement
for the first 24 h and then proceeded to recover and regain a
normal appearance over the next 48 h. The C57BL/6 mice then
appeared healthy until euthanasia at the end of the experi-
ment. In contrast, the CD1d/ mice had similar symptoms
that were noticeably worse and also displayed curled forelimbs
and a slight tremor. The CD1d/ mice made a partial recov-
ery over the course of the experiment, but by day 12 they still
had slower movement, hunched posture, tremor, and ruffled
fur. These data indicate that NKT cells make substantial con-
tributions to Ab responses that maintain the health of the
animal following a lethal challenge with toxin.
Given that a fairly low Ab titer correlated with survival but
not good health in the CD1d/ mice, it was anticipated that
in vivo challenge with the 200-g dose would not reveal sur-
vival differences between C57BL/6 mice immunized with PA
versus PA plus -GC. In light of this observation and a recent
report elegantly demonstrating that multiple doses of toxin
could be used to tease apart genetic differences in susceptibility
in vivo (22), we performed a challenge experiment using a
200-g dose of LT on day 0 followed with a second 100-g
dose on day 2 (Fig. 3c). We observed that PA-immunized mice
died rapidly, while three of five mice immunized with PA plus
-GC survived. The surviving mice were initially symptomatic
and then appeared healthy within 48 h of the second toxin
challenge. These data are consistent with the in vitro challenge
data (Fig. 2), and this indicates that -GC leads to increased
resistance to higher amounts of LT.
NKT activation leads to a sustained protective antibody
response. We performed experiments to determine if -GC-
activated NKT cells play a role in the development of a sus-
tained protective anti-PA Ab response. We immunized
C57BL/6 mice with PA or PA plus -GC and administered a
PA booster on day 28 as described in Materials and Methods.
We then collected sera at different time points over a period of
141 days (Fig. 4). Consistent with the results shown in Fig. 1,
shortly after the booster vaccine there was a lower anti-PA Ab
titer in C57BL/6 mice immunized with PA alone than with PA
plus -GC (Fig. 4a). In both groups the total anti-PA IgG1
titer was sustained for the duration of the experiment. Of note,
the absolute Ab titers and neutralization titers were lower than
in other experiments because a lower dose of PA (8 g) was
used and a higher dose of -GC was used (4 g). This allowed
us to better measure the adjuvant effect of -GC. Further-
more, we had observed a fairly well sustained Ab titer follow-
ing immunization with PA alone at higher doses (data not
shown) and reasoned that a lower dose might lead to a less
sustained anti-PA Ab titer that could be boosted with -GC.
There was a gradual decline in the in vitro neutralization of
LT by the sera collected over the 141-day period of the exper-
iment (Fig. 4c). However, the samples from the PA/-GC-
immunized mice consistently had a higher neutralizing Ab titer
than the samples from the PA-immunized mice. We performed
additional analyses on our neutralization assay data, whereby
the rate of decay of the neutralizing Ab responses was mea-
FIG. 4. -GC leads to sustained protective anti-PA Ab responses.
C57BL/6 mice were immunized with 8 g of PA alone or PA plus 4 g
of -GC and then boosted 28 days later with 4 g of PA alone. Sera
were collected at the times indicated before and after booster admin-
istration. (a) Endpoint anti-PA IgG1 titers were determined. Data
show geometric mean titers (
 the 95% confidence interval) for nine
mice per group. (b) In vitro neutralization of toxin was assessed at the
times shown. Data show the mean percent neutralization for nine mice
per group. (c) After 160 days, mice were challenged i.v. with 200 g of
PA and LF on day 0 and 100 g of PA and LF on day 1 (as indicated
by arrows). Survival was then monitored daily. Five mice per group
encompassing the range of endpoint anti-PA titers were selected for
the challenge experiment. Of the original nine mice, the remaining
four mice per group were used for analysis of bone marrow PA-specific
plasma cells. However, the sensitivity of the assay was low and the data
are not reported here.
1614 DEVERA ET AL. INFECT. IMMUN.
sured. The mean times required for a 50% drop in neutraliza-
tion activity were 22 days and 60 days for the PA and PA/-GC
groups, respectively (data not shown). This reinforces the con-
cept that NKT activation leads to a more sustained protective
anti-PA Ab response.
We then determined whether PA/-GC immunization could
lead to sustained protection against LT in vivo (Fig. 4c). In this
experiment, 160 days after the initial immunization, PA/-GC-
immunized mice did not succumb to the lethal challenge,
whereas every mouse in the PA-immunized group died within
4 days of receiving LT. These data show that activation of type
I NKT cells with -GC at the time of the primary immuniza-
tion leads to the development of a sustained protective Ab
response in vivo.
DISCUSSION
We have demonstrated for the first time that CD1d-re-
stricted NKT cells are important for the generation of specific
protective Ab responses against B. anthracis LT. Our data
showed that coadministration of a CD1d-binding glycolipid
(-GC) which activates type I NKT cells led to a 4-fold in-
crease in the endpoint PA-specific serum Ab titer. The -GC
molecule was unable to increase Ab titers in CD1d/ mice
lacking type I and type II NKT cells and J18/ mice lacking
type I NKT cells. These data indicate that foreign CD1d-
binding glycolipids may have utility as adjuvants for inducing
protective Ab titers against LT. This may be particularly im-
portant for the current anthrax vaccine, for which multiple
boosters are required to maintain protection. In our study, one
immunization and one booster elicited sustained in vivo pro-
tection against a lethal challenge with LT.
Efforts are under way to understand the mechanisms by
which NKT cells enhance Ab responses and to understand how
this differs from the stimulation provided by CD4 helper T
cells (Th). PA immunization leads to Th-dependent Ab re-
sponses (15, 25). Th cells utilize cytokine- and CD154-depen-
dent mechanisms to drive the differentiation of B cells into
Ab-secreting cells via cytokine receptor and CD40 signaling,
respectively (23). This process is known broadly as B-cell help.
We have demonstrated that vaccination with PA/-GC leads to
a superior and durable PA-protective Ab response compared
to PA immunization, suggesting that there could be mechanis-
tic differences between NKT- and Th-mediated B-cell help. At
present, researchers do not sufficiently understand the mech-
anisms by which -GC-stimulated type I NKT cells help B cells
to be able to make an adequate comparison with Th cells.
However, we and others have shown that cognate interac-
tions between CD1d/ B cells and NKT cells are required for
-GC-enhanced Ab responses (2, 16, 19). Therefore, B cells
that present PA-derived peptides on MHC class II likely have
to copresent -GC on CD1d to provide a coordinated activa-
tion of CD4 Th cells and NKT cells. This potentially explains
why -GC/NKT-enhanced Ab responses are Ag specific and
indicates that -GC could be a useful adjuvant for boosting
PA-specific Ab responses.
One group has also suggested that NKT-derived gamma
interferon (IFN-) and interleukin-4 (IL-4) could be important
for -GC-enhanced Ab responses (11). However, NKT-de-
rived cytokines were not examined specifically, because knock-
out mice in which all T cells lacked IFN- and IL-4 were used.
Nonetheless, this raises the intriguing possibility that NKT
cells provide direct help to PA-specific B cells via cytokine
signals. There is also evidence that CD154-expressing NKT
cells mediate help for Ab production via cognate interactions
with B cells expressing CD40. In our previous studies we
showed that a combination of T-dependent Ag, -GC, and an
agonistic anti-CD40 MAb could induce a limited specific Ab
response in class II null mice (17). Another group recently
confirmed our findings (11) but as yet, NKT-specific CD154
signals have not been examined.
The studies herein demonstrate that NKT activation pro-
grams the B-cell response to lead to durable protective Ab
responses. Although there is likely some commonality in the
mechanism of B-cell help with that provided by Th cells, there
are logically some differences, given the distinct immunological
outcomes. Future studies will determine how Th-derived B-cell
help differs from Th/NKT-derived B-cell help, and use of PA
as the immunizing Ag may help determine the mechanisms.
When no adjuvant was added to the vaccine, PA induced a
robust specific Ab response, in accordance with the findings of
several other investigators (1, 21, 25, 26, 28, 33). While the Ab
response against PA alone was defective in CD1d/ mice, in
J18/ mice the Ab response was comparable to the C57BL/6
control strain. This implicates type II NKT cells in the induc-
tion of specific Ab responses against PA. Since no foreign
CD1d ligand was added, a self-CD1d Ag could be directing
anti-PA Ab responses via type II NKT cells. Few self-Ags for
CD1d have been identified but include sulfatide, which can
activate type II NKT cells (12). However, a mechanism by
which type II NKT cells contribute to humoral immunity is
presently unclear. An alternative explanation for the defect in
anti-PA Ab responses in CD1d/ mice is that type II NKT
cells make a contribution to the development and/or function
of the B-cell compartment. Compared to C57BL/6 mice we
have observed up to 50% fewer numbers of a bone marrow-
resident cell population in CD1d/ mice that is consistent
with plasma cell precursors (H. B. Shah and M. L. Lang,
unpublished observation). However, two observations argue
against the reduced plasma cell precursor population as an
explanation for our present results. First, the anti-PA Ab re-
sponse is 10-fold lower in CD1d/ mice than in C57BL/6
mice. Secondly, our earlier findings showed that if the NKT
pathway is bypassed by adsorption of foreign Ags to alum
adjuvant, then good Ab titers can be achieved in CD1d/
mice (8). Future studies will therefore explore the contribution
of type II NKT cells to anti-PA Ab responses.
Importantly, the sera obtained from C57BL/6 mice previ-
ously immunized with PA plus -GC were able to neutralize
higher concentrations of lethal toxin in vitro than sera from
mice previously immunized with PA alone. This shows that an
enhanced protective Ab response is induced by immunization
with PA and CD1d-binding glycolipid Ags. Conversely, sera
from CD1d/ mice did not provide good in vitro neutraliza-
tion of LT. Therefore, the total anti-PA Ab titer was generally
indicative of in vitro neutralization titers. Since sera from
CD1d/ mice did not effectively neutralize LT in vitro, this
suggests that as well as lower amounts of anti-PA Ab, the
affinity of the Ab could be important. While we previously
reported that CD1d/ mice had a lower proportion of high-
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affinity Ab than C57BL/6 controls when a model antigen (ni-
trophenol-conjugated keyhole limpet hemocyanin) was used
(8), we did not observe differences in the proportion of high-
affinity anti-PA Ab by ELISA (data not shown). NKT cells
could play a role in anti-PA Ab affinity maturation that is not
detectable in our assay, and investigation of Ab hypermutation
in future studies is warranted.
For reasons that are not entirely clear, the total anti-PA Ab
was sustained over a 141-day period, yet in vitro neutralization
showed a moderate decline. We suggest that a small decline in
anti-PA Ab that is not detectable in the ELISA is more de-
tectable in the in vitro assay. The in vivo protection against
lethal challenge with LT was sustained over at least the same
period. This suggests that anti-PA Ab that recruits effector
functions in vivo contributes to sustained protection. A small
decline in the amount of Ab may be more important for the in
vitro assay, which does not utilize effector functions to prevent
toxin activity on target cells.
Our most striking finding was that type I NKT activation
with -GC led to sustained protection in vivo against LT.
While there was some resistance among PA-immunized
C57BL/6 and CD1d/ mice challenged with a single dose of
LT, a second dose of LT revealed better protection in PA/-
GC-immunized C57BL/6 mice. When we used this method,
PA-immunized mice succumbed rapidly to LT, while PA/-
GC-immunized mice were resistant. This effect was apparent 7
days after the vaccination course was complete but even more
apparent on day 141 postimmunization. This represents a sig-
nificant advance in the understanding of how to generate more
sustained Ab-mediated protection against LT and may contrib-
ute to overcoming the major limitation of the current vaccine.
This could be important in the clinical setting. Apart from
practical considerations, a shorter vaccination protocol among
at-risk individuals will likely increase compliance. More-sus-
tained protection against B. anthracis and fewer vaccination-
associated inflammatory responses may also be achieved.
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